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WHAT THIS PAPER ADDS
 Our work focussed on a new biomarker for predicting vulnerability of carotid plaque, the plasmatic level of lipoprotein-associated
phospholipase A2. We reported that Lp-PLA2 is increased in patients with unstable and high-grade carotid stenosis.
 Lp-PLA2 may thus be a relevant biomarker that could classify a carotid plaque as vulnerable or not, and predict neurologic risk of
a carotid stenosis in asymptomatic subjects.a r t i c l e i n f o
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Objective: To test plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) in patients with
high-grade carotid stenosis according to plaque histology.
Methods: This cross-sectional single-centre study included patients with 70% North American Symp-
tomatic Carotid Endarterectomy Trial (NASCET) carotid stenosis, who were treated surgically. Serum Lp-
PLA2 and high-sensitivity C-reactive protein (hs-CRP) were determined on the day of surgery. Histo-
pathological analysis classiﬁed carotid plaque as stable or unstable, according to AHA classiﬁcation.
Results: Of the 42 patients (mean age 70.4 10.5 years; 67%men), neurological symptomswere present in
16 (38%). Unstable plaqueswere found in 23 (55%).Medianplasma level of Lp-PLA2was signiﬁcantly higher
in patients with unstable plaque compared to those with stable plaque (222.4 (174.9e437.5) interquartile
range (IQR) 63.5 vs. 211.1 (174.9e270.6) IQR 37.2 ng ml1; p¼ 0.02). Moreover, median Lp-PLA2 level were
higher in asymptomatic patients with unstable plaque (226.8 ng ml1 (174.9e437.5) IQR 76.8) vs. stable
plaque (206.9 ng ml1 (174.9e270.6) IQR 33.7; p ¼ 0.16). Logistic regression showed that only the neuro-
logical symptoms (OR ¼ 30.9 (3.7e244.6); p < 0.001) and the plasma Lp-PLA2 level (OR ¼ 1.7 (1.1e12.3);
p ¼ 0.03) were independently associated with unstable carotid plaque as deﬁned by histology.
Conclusions: This study showed that circulating Lp-PLA2 was increased in patients with high-grade
carotid stenosis and unstable plaque. Lp-PLA2 may be a relevant biomarker to guide for invasive
therapy in asymptomatic patients with carotid artery disease.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.tions on this paper, please go
al de la Timone, 264 rue saint
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ciety for Vascular Surgery. PublisheSystematic surgery of patients with 70% North American
Symptomatic Carotid Endarterectomy Trial (NASCET)1 asymptom-
atic carotid stenosis is actually debated. This reﬂects the consider-
able improvement in medical treatment not only by strict control ofd by Elsevier Ltd. All rights reserved.
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anti-platelet therapy, statins and angiotensin-converting enzyme
(ACE) inhibitors. This medical approach may reduce the risk of
stroke inherent with carotid stenosis to levels below the stroke-risk
due to surgery.2 However, for some patients, despite this best
medical treatment, the risk of carotid stenosis is not completely
abolished and additional surgery can be useful, especially in
patients who would otherwise have >10 years of life expectancy.3
In this context, several markers have been tested to select
patients who would most beneﬁt from surgery: systemic biological
markers (high-sensitivity C-reactive protein (hs-CRP),
metalloproteinase-2 MMP-2 and MMP-9)4 and imaging techniques
(contrast ultrasound, high-resolution magnetic resonance imaging
(MRI) and nuclear techniques) have been assessed for their ability
to detect unstable carotid plaques. Recently, lipoprotein-associated
phospholipase A2 (Lp-PLA2) has been considered as an original
independent biomarker of both coronary heart disease and
ischaemic stroke associated with atherosclerosis.5 Lp-PLA2 is
a calcium-independent member of the phospholipase A2 enzyme
family, and can hydrolyse oxidised phospholipids to generate
lysophosphatidylcholine and oxidised fatty acids, which have
proinﬂammatory properties. Lp-PLA2 is secreted de novo by plaque
inﬂammatory cells6 and is thus implicated in the genesis of
vulnerable plaques. In 2008, an international consensus panel
included a level of Lp-PLA2 >200 ng ml1 as a new parameter to
improve the stratiﬁcation of CV-risk patients.7 Recently, Mannheim
et al. showed that local expression of Lp-PLA2 in carotid plaque is
increased in patients with clinical vulnerable plaque.8
The objective of our study was to compare plasma levels of Lp-
PLA2 in patients with high-grade carotid stenosis according to
plaque histology.
Materials and Methods
Patients
Patients with high-grade carotid stenosis, who were referred to
our vascular surgery department for a carotid endarterectomy,were
included from June 2009 to June 2010. All symptomatic patients had
a clinical evaluation by a neurologist, a brain imaging and cardiac
examinations (trans-oesophageal echocardiography and electro-
cardiogram (ECG) monitoring). Informed consent was obtained
fromall patients. All procedureswere approved by the local human-
ethics committee. High-grade carotid stenosis was deﬁned by
a 70% diameter reduction using the NASCET method.1 All the data
were collectedprospectively. Hypercholesterolaemiawas deﬁned as
low-density lipoprotein (LDL) cholesterol >160 mg dl1 or long-
term statin therapy. Medical therapy was deﬁned as the treatment
at the admission in our vascular surgery department. NASCET clin-
ical criteria1 were used to classify patients as neurologically symp-
tomatic or asymptomatic. Patients with clinical signs of infection
were excluded. A carotid endarterectomy was performed using
conventional surgical techniques and removed carotid plaque was
collected for histopathological analysis.
Laboratory measurements
On the day of surgery, blood samples were taken for subsequent
analysis (hs-CRP and Lp-PLA2), and plasma were stored at 70 C
until analysis. Lp-PLA2 was measured using the PLAC Test (dia-
Dexus Inc., SanFrancisco, CA,USA) test,whichusesadualmonoclonal
antibody immunoassay, which was standardised to recombinant Lp-
PLA2.9 Hs-CRP was measured using the SYNCHRON LX PRO System,
which has been validated to the Beckman Coultermethod. Biological
analyses were performed blinded to the clinical details.Histological assessment and immunohistochemistry of carotid
plaques
The samples were ﬁxed for 24 h in 4% neutral buffered formalin,
dehydrated in graded alcohols, cleared in xylene and embedded in
parafﬁn. Serial (5 mm) samples were cut for haematoxylineeosin
staining (HES) and immunohistochemical procedures to identify
speciﬁc antibodies. Automated immunohistochemistry was per-
formed with an avidinebiotineperoxidase complex using a Ven-
tana Benchmark XT. The following antibodies were used: anti-CD 3
(polyclonal rabbit anti-human, Dako, pre-diluted 1/2) and anti-CD
68 (monoclonal mouse anti-human clone KP1, Dako, diluted 1/
2500).
Morphological characteristics of the carotid plaque were
established on HES sections according to the classiﬁcation of the
American Heart Association (AHA)10 (Fig. 1). Lesions referred to as
stablewere AHA type V, characterised by ﬁbrous conjunctive tissue,
together with extracellular lipids and laminated acellular collagen,
without any endothelial disruption (Va), or were only ﬁbrous
conjunctive tissue (Vb). Lesions referred to as unstable were type
VI, characterised by ulceration of the endothelial surface (VIa) or
recent intra-plaque haemorrhage (VIb), or an intra-plaque throm-
bosis (VIc). Six sections per patient were analysed. The quantiﬁca-
tion of T lymphocytes and macrophages was established from
immunohistochemical sections that were taken from the area
around the lipid core. Quantitative evaluation of 10 optical ﬁelds
was performed at 400 magniﬁcation. Results are expressed as the
number of cells per 10 ﬁelds.
Statistical analyses
The patients’ characteristics were compared at baseline
according to the plaque’s morphology and the presence of neuro-
logical symptoms in the patient. Results were expressed as
mean  standard deviation (SD) or median (minemax) with
interquartile range (IQR). Bivariate analyses were conducted with
all appropriate continuous variables using Student’s t-test or
a ManneWhitney test. Categorical variables were analysed by the
chi-squared or Fisher’s exact test. The statistical analysis was
considered to be signiﬁcant for p < 0.05. Multivariate analysis was
carried out by elaborating a logistic regression model to estimate
the probability of an unstable plaque according to the relevant
parameters. The selection of variables was made according to
a literature review11 and the results of bivariate analyses (variables
associated with p < 0.05): age, sex, the existence of a hyper-
cholesterolaemia, the presence of neurological symptoms, the Lp-
PLA2 level and the hs-CRP level. Analysis was performed using R
for Windows, version 2.11.1.
Results
Population characteristics
A total of 42 patients (28 men and 14 women) were included
with a mean age of 70.4  10.6 years. During the inclusion period,
30 patients were not included because of unavailable biological or
histological samples or patients’ rejection. Neurological symptoms
were present in 16 patients (38%): ﬁve (31%) had a transient
ischaemic attack (three with hemispheric symptoms and two with
amaurosis fugax) and 11 (69%) had a stroke. Mean carotid-diameter
reduction was 82.8  8.6%. At hospital admission, 41 patients
(98.0%) were receiving anti-platelet therapy, 26 (61.9%) were
receiving statins and 18 (42.9%) were receiving ACE inhibitors. All
patients warranted that they took their treatment. The mean time
between neurological symptoms and carotid surgery was 11.4  7.2
Figure 1. Examples of stable (A) and unstable plaque (B) obtained by histological analysis according to the American Heart Association’s classiﬁcation.19 A: Plaque deﬁned as stable
(AHA type V) are characterised by a small lipid core (1) and a large ﬁbrous cap (2) on haematoxylineeosin staining (HES). Original magniﬁcation 200. B: Plaque deﬁned as unstable
(AHA type VI) are characterised by a thin ﬁbrous cap (3), a large and altered lipid core (4), and an intra-plaque thrombosis with rupture of the cap (5) on HES-staining. Original
magniﬁcation 100.
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unstable (55%, n ¼ 23) or stable (45%, n ¼ 19). The most frequently
encountered cells were macrophages (mean per 10 ﬁelds:
33.6  15.3) more than T lymphocytes (mean per 10 ﬁelds:
13.5  11.7).
Characteristics for all patients regarding ‘neurological symp-
toms’ vs. the ‘asymptomatic’ patients, and ‘unstable plaques’ vs.
‘stable plaques’, are summarised in Table 1. There was no statistical
difference regarding age, gender, CV-risk factors, prior history of
coronary artery disease or peripheral artery disease, or medical
therapy. Hypercholesterolaemia was more frequent in asymptom-
atic patients and in patients with stable plaques (p ¼ 0.04).
Unstable plaque was signiﬁcantly associated with the presence of
neurological symptoms (p ¼ 0.001) and with the number of
macrophages in the plaque (p ¼ 0.02). There was no association
between high-density lipoprotein (HDL) and Lp-PLA2.
Plasma Lp-PLA2, neurological symptoms and carotid-plaque
morphology
Median plasma level of Lp-PLA2 in the total patient population
was 214.6 ng ml1 (174.9e437.5). Thirty-one patients (74%) had an
Lp-PLA2 level 200 ng ml1, 18 patients had unstable plaque (78%,
n ¼ 23) and 13 had stable plaque (68%, n ¼ 19, p ¼ 0.18). Median
plasma level of Lp-PLA2 was signiﬁcantly higher in patients with
unstable plaque including ulcerated plaque compared to thosewith
stable plaque (222.4 (174.9e437.5) IQR 63.5 vs. 211.1 (174.9e270.6)
IQR 37.2 ng ml1; p ¼ 0.02) (Fig. 2). There was no signiﬁcantTable 1
Clinical and therapeutic characteristics of all patients and of those with neurological sym
All patients Neurological symptom
n ¼ 42 (%) No Y
n ¼ 26 (%) n
Age (years; mean  SD) 70.4  10.6 72.2 6
Male gender 28 (66.6) 16 (61.5) 1
Body-mass index (mean) 26 26.1 2
Hypertension 32 (76.2) 22 (84.6) 1
Diabetes mellitus 7 (16.7) 6 (23.1)
Hypercholesterolaemia 30 (71.4) 22 (84.6)
Smoker 13 (31.0) 8 (30.8)
CAD or PAD 15 (35.7) 9 (34.6)
Antiplatelets 41 (98.0) 26 (100) 1
Statins 26 (61.9) 18 (69.2)
Neurological event 16 (38.1) 0 (0) 1
Unstable plaque 23 (54.8) 8 (30.8) 1
Macrophages CD68 (mean  SD) 33.6  15.3 32.8 3
T lymphocytes CD3 (mean  SD) 13.5  11.7 13.3 1
CAD: coronary artery disease, PAD: peripheral artery disease.difference between patients with or without neurological symp-
toms (220.0 (182.2e349.7) IQR 62.6 vs. 213.0 (174.9e437.5) IQR
33.7 ng ml1; p ¼ 0.43) (Fig. 2).
Plasma hs-CRP, neurological symptoms and carotid-plaque
morphology
Median plasma level of hs-CRP in the total patient population
was 4.7 mg l1 (0.5e83). This was signiﬁcantly higher in patients
with unstable plaque compared to those with stable plaque (11.0
(1e83) IQR 16.8 vs. 2.0 (0.5e25) IQR 3.5 mg l1; p ¼ 0.01) (Fig. 3).
Similarly, median plasma level of hs-CRP was signiﬁcantly higher in
patients with neurological symptoms compared to asymptomatic
patients (12.0 (2e83) IQR 19.0 vs. 1.9 (0.5e25) IQR 3.0 mg l1;
p ¼ 0.009) (Fig. 3).
Lp-PLA2 and hs-CRP plasma levels in asymptomatic patients with
unstable carotid plaques vs. stable plaques
In patients without neurological symptoms, eight had unstable
plaques and 18 had stable plaques, as assessed by histology. Char-
acteristics were identical whatever the carotid-plaque morphology
(Table 2). Plasma Lp-PLA2 was higher in patients with unstable
plaques compared to those with stable plaques (226.8
(174.9e437.5) IQR 76.8 vs. 206.9 (174.9e270.6) IQR 33.7 ng ml1;
p ¼ 0.16) (Fig. 2). However, hs-CRP levels were similar between
patients with unstable or stable plaques (2.8 (1e13.6) IQR 6.5 vs. 1.9
(0.5e25) IQR 3.0 mg l1; p ¼ 0.53) (Fig. 3).ptoms or a plaque morphology.
s Plaque morphology
es p Stable Unstable p
¼ 16 (%) n ¼ 19 (%) n ¼ 23 (%)
7.4 0.18 73.1 68.2 0.14
2 (75.0) 0.57 12 (63.2) 16 (69.6) 0.91
5.8 0.80 26 25.9 0.95
0 (62.5) 0.20 17 (89.5) 15 (65.2) 0.14
1 (6.2) 0.31 5 (26.3) 2 (8.7) 0.27
8 (50.0) 0.04 17 (89.5) 13 (56.5) 0.04
5 (31.2) 0.75 5 (26.3) 8 (34.8) 0.79
6 (37.5) 0.64 6 (31.5) 9 (39.1) 0.61
5 (93.8) 0.77 19 (100) 22 (95.7) 0.83
8 (50.0) 0.20 13 (68.4) 13 (56.5) 0.30
6 (100) e 1 (5.0) 15 (65.0) 0.001
5 (93.7) 0.001 0 (0) 23 (100) e
4.8 0.87 27.7 38.4 0.02
3.9 0.70 11.5 15.0 0.19
Figure 2. Box and whisker plots representing circulating Lp-PLA2 levels in patients with regard to plaque morphology or/and neurological symptoms. Circulating Lp-PLA2 levels
were signiﬁcantly increased in patients with unstable plaque (p ¼ 0.02). The bottom and top of the box represent the 25th and 75th percentile and the band near the middle of the
box is the median. The ends of the whiskers represent the lowest datum still within 1.5 interquartile range of the lower quartile, and the highest datum still within 1.5 interquartile
range of the upper quartile.
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After logistic regression, only the presence of neurological
symptoms and elevated plasmatic Lp-PLA2 levels were indepen-
dently associated with unstable plaque. The risk of unstable carotid
plaque was increased 1.7-fold to an Lp-PLA2 level of 200 ng ml1
(OR ¼ 1.7 (1.1e12.3); p ¼ 0.03) and was 30.9 times more with
neurologic symptoms (OR ¼ 30.9 (3.7e244.6); p < 0.001). This
result was not improved when hs-CRP level was associated to Lp-
PLA2 level.
Discussion
Our study shows that the patients with high-grade carotid
stenosis and unstable plaques have a signiﬁcantly higher plasmatic
Lp-PLA2 level than patients with stable plaques. These ﬁndings
strongly suggest a role for Lp-PLA2 in the pathophysiology and
clinical presentation of unstable carotid stenosis, thus supporting
the report of Mannheim et al. in 2008.8 These authors enrolled 167
patients who had undergone a carotid endarterectomy; they found
increased local expression of Lp-PLA2 in symptomatic patients and
vulnerable plaque. These results may be interesting to predict
neurological risk of a carotid stenosis in asymptomatic patients in
whom surgery is actually highly debated given the low rate of
stroke with the best medical therapy.2,3
Interest in Lp-PLA2 as a biomarker for CV disease emerged 10
years ago after WOSCOPS publication (West of Scotland Coronary
Prevention Study, WOSCOPS), which showed a positive association
between elevated circulating concentrations of Lp-PLA2 and theFigure 3. Box and whisker plots representing hs-CRP levels of patients with regard to plaque
in patients with unstable plaque (p ¼ 0.01) and neurological symptoms (p ¼ 0.009).risk of coronary events.12 Since then, several reports have
conﬁrmed these results in coronary artery and cerebrovascular
diseases.13 Although some reports inconclusively found this posi-
tive association,14 two recent meta-analyses and one review have
conﬁrmed that, after multivariate adjustments, increased levels of
Lp-PLA2 remain a reliable marker for increased risk of CV
events.5,15,16
In this study, we chose to measure the mass of Lp-PLA2 without
analysing its activity. Lp-PLA2 is an enzyme that can be measured
by either its mass or its activity. In a recent meta-analysis, Madjid
et al. found 16 studies that measured mass, 12 studies that
measured activity and six that included both mass and activity.15
Currently, there is no consensus on the best method to estimate
Lp-PLA2 level. However, in 2008, a panel’s recommendation, which
incorporated Lp-PLA2 testing into the CV disease-risk assessment
guidelines, used mass to measure Lp-PLA2 when stratifying
patients.7 Recently, the US Food and Drug Administration approved
the immunoassay PLAC test, which measures Lp-PLA2 mass to
screen patients who are at high risk of CV disease. In this context,
we have preferred to assess the mass of Lp-PLA2, and not its
activity. However, a large-scale, randomised, multicentre trial is
needed to determine which assay method is superior.
Our study reports that patients with neurological symptoms, or
with unstable carotid plaque, have hs-CRP levels signiﬁcantly
higher than asymptomatic patients or those with stable plaque.
Similarly, Alvarez et al., in 2003, reported this correlation in 62
patients with high-grade carotid stenosis.4 Moreover, after logistic
regression, Lp-PLA2, but not hs-CRP, was independently associated
with unstable plaque, as deﬁned by histology. Elkind et al. studiedmorphology or/and neurological symptoms. Hs-CRP levels were signiﬁcantly increased
Table 2
Clinical and therapeutic characteristics of asymptomatic patients regarding plaque
morphology.
Plaque morphology
Stable Unstable p
n ¼ 18 (%) n ¼ 8 (%)
Age (years; mean  SD) 72.9  10.7 70.6  6.4 0.53
Male gender 11 (61.1) 5 (62.5) 0.71
Body-mass index (mean) 26.3 25.6 0.59
Hypertension 16 (88.9) 6 (75.0) 0.75
Diabetes mellitus 5 (27.8) 1 (12.5) 0.72
Hypercholesterolaemia 16 (88.9) 6 (75.0) 0.75
Smoker 5 (27.8) 3 (37.5) 0.66
CAD or PAD 6 (33.3) 3 (37.5) 0.68
Antiplatelets 18 (100) 8 (100.0) 0.57
Statins 13 (72.2) 5 (62.5) 0.97
Macrophages CD68 (mean  SD) 28.3  14.2 42.9  13.6 0.03
T lymphocytes CD3 (mean  SD) 11.5  10.5 17.2  12.0 0.26
CAD: coronary artery disease, PAD: peripheral artery disease.
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stroke and concluded that Lp-PLA2, but not hs-CRP, was associated
with the recurrence of ischaemic neurological events.17 In addition,
a biovariability study on samples from 43 non-fasting healthy
adults reported greater stability of Lp-PLA2 compared to hs-CRP
levels in peripheral blood.18 All these results suggest that
enhancement of hs-CRP may be a consequence of stroke and that
Lp-PLA2 is more relevant than hs-CRP to predict vulnerability of
carotid plaques.
Pathophysiological mechanisms that explain the association
between circulating Lp-PLA2 and unstable atherosclerosis plaques
are unclear and complex; however, a pro-atherogenic biological
role for Lp-PLA2 has ever been suggested before. Lp-PLA2 has been
shown to promote modifcation of LDL, to enhance binding to
matrix proteoglycans, and to facilitate their aggregation and
oxidation. The accumulation of such modiﬁed LDL in the intimal
subendothelial space is a key initiation step in endothelial activa-
tion and atherosclerotic-plaque rupture.15,16 Locally, Lp-PLA2 has
been detected in human carotid atherosclerotic plaques, but not in
areas of the adjacent normal arterial wall.19 Its expression is mainly
conﬁned to plaque areas with massive lipid accumulation and
leucocyte inﬁltration, cellular necrosis and calciﬁcation: this
suggests that Lp-PLA2 is amarker for unstable plaque. As Lp-PLA2 is
produced by macrophages and foam cells within atherosclerotic
vulnerable plaques, excessive Lp-PLA2 may be released into
peripheral blood and, thus, could indicate these unstable plaques.
Study limitations are the small number of asymptomatic
patients who do not allow to obtain a signiﬁcant association
between Lp-PLA2 and unstable plaque, even though the trend is
strong. Also, we were not able to determine a cut-off point for Lp-
PLA2 to classify patients but we demonstrated that the risk of
unstable carotid plaque was increased 1.7-fold to an Lp-PLA2 level
of 200 ng ml1, which is the cut-off point used by the interna-
tional consensus on Lp-PLA2 to classify the level of CV risk.7
Moreover, we used as deﬁnition of hypercholesterolaemia: LDL
cholesterol >160 mg dl1 or long-term statin therapy. With this
deﬁnition, we obtained signiﬁcantly more patients with hyper-
cholesterolaemia in asymptomatic patients and in stable plaque
because these patients ever took statin therapy for CV diseases or
carotid stenosis. However, logistic regression showed that Lp-PLA2
was correlated to plaque instability whatever level of hyper-
cholesterolaemia. Finally, Lp-PLA2 may reﬂect a systemic state of
vulnerable atherosclerosis without localising the real culprit lesion.
Several teams have developed imaging techniques, using contrast
ultrasound, high-resolution MRI and nuclear imaging to analyseparameters of instability, such as intra-plaque haemorrhage or
a thrombus. A multi-marker strategy that coupled biology and
imaging could improve identiﬁcation of at-risk asymptomatic
atherosclerotic lesions to guide effective therapy.Conclusions
We have shown in this preliminary study that circulating Lp-
PLA2 was increased in patients with unstable carotid stenosis.
These ﬁndings strongly support a role for Lp-PLA2 in the patho-
physiology and clinical presentation of carotid artery disease. Lp-
PLA2 may be a relevant biomarker that could identify vulnerable
carotid stenosis. Further studies are warranted to conﬁrm these
preliminary results and to determine a threshold value to predict
the neurological risk of a carotid stenosis in asymptomatic subjects.Acknowledgements
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